Applications of Methyl (2R,3S)-3-(Benzoylamino)-2-Hydroxy-3-Phenylpropanoate in Industrial Manufacturing

Methyl (2R,3S)-3-(Benzoylamino)-2-Hydroxy-3-Phenylpropanoate serves as a key chiral intermediate in a range of industrial chemical syntheses, especially within active pharmaceutical ingredient (API) production, advanced peptide synthesis, and select specialty chemical manufacturing. This substance’s stereochemical integrity and purity meet regulatory demands in strictly regulated sectors, and our production adheres to stringent quality controls responding to real, high-value downstream applications. Below we clarify actual industrial use cases, detailing integration points, regulatory context, dosage practices, and typical end products.

1. Chiral Pharmaceutical Intermediate for Antihypertensive Drugs

Our production of this compound supports the pharmaceutical synthesis of chiral non-proteinogenic amino acid derivatives used in the development of select antihypertensive APIs, notably during the enantioselective stages of target molecule building. Downstream manufacturers formulate it into high-value intermediates, where precise configuration controls activity and pharmacokinetics. The dosage into the synthetic sequence depends on the specific stoichiometry required for the enantiopure outcome, and all stages require traceability and full documentation to satisfy regulatory audits.

Industry compliance standards

• Good Manufacturing Practice (GMP) as per ICH Q7 guidelines
• United States Pharmacopeia (USP) specifications on raw materials
• European Pharmacopoeia (Ph. Eur.) monograph requirements for chiral intermediates
• FDA 21 CFR Part 210/211 for finished pharmaceutical operations

Typical usage ratio

• 0.65 – 1.05 equivalents, adjusted per reaction stoichiometry in the condensation or amidation step
• Batch sizes from 5 kg to 250 kg per phase depending on target output and pilot or commercial scale

Downstream process integration

• Direct enantioselective introduction in the early synthesis of beta-hydroxy amino acid subunits
• Incorporation during peptide coupling using carbodiimide reagents or similar activating agents
• Followed by purification through chromatography before subsequent hydrolysis or enzymatic transformation

Final product types

• Chiral intermediates for antihypertensive APIs (e.g., ACE inhibitor derivatives)
• Active pharmaceutical ingredients after further functional group transformation
• Intermediates for orally administered tablet or capsule forms

2. Peptide Synthesis Building Block for Advanced Peptidomimetics

In the peptide synthesis industry, this compound provides a stereochemically-defined residue essential for the assembly of specialty peptides and peptidomimetic drug candidates. Owing to its N-benzoyl protection and methyl ester terminus, downstream formulators can incorporate it selectively during resin-bound or solution-phase synthesis, while maintaining configurational stability. The introduction ratio is dictated by the solid-phase loading or molar equivalence relative to neighboring amino acid analogs.

Industry compliance standards

• ISO 9001:2015 Quality Management for specialty chemical processing
• ICH Q11 guidelines for API starting material management
• Current Good Manufacturing Practice (cGMP) for peptide production
• Relevant US FDA DMF (Drug Master File) recommendations for peptide API synthesis

Typical usage ratio

• Esentially 1.00 molar equivalent per target residue in peptide assembly
• Loadings vary – typically 0.2 – 1.2 mmol/g resin, tailored to product sequence length and coupling chemistry

Downstream process integration

• Solid-phase peptide synthesis (SPPS), introduced as a building block while monitoring racemization
• Activated prior to base- or acid-labile deprotection stages
• Sequential extension for the generation of peptide backbones or peptidomimetic scaffolds

Final product types

• Therapeutic peptides with enhanced stability
• Peptidomimetic drug candidates for preclinical evaluation
• Research-grade synthetic peptide fragments

3. Chiral Starting Material for β-Lactam Antibiotic Side Chains

Manufacturers of β-lactam antibiotics deploy this compound as a stereoselective precursor in the synthesis of tailored side chains, impacting the antimicrobial spectrum of the final API. Its use enhances the defined chirality throughout the acylation or condensation sequence, often critical in regulatory submissions and batch traceability. The addition rate responds to the overall process mass balance and efficiency demands for both pilot and commercial drug synthesis.

Industry compliance standards

• WHO Good Manufacturing Practices for pharmaceutical production
• European Pharmacopoeia (Ph. Eur.) and USP standards for antibiotic intermediates
• Quality system certification to ISO 14001 for responsible chemical production
• Documentation aligned with US FDA QSR requirements when destined for clinical supply

Typical usage ratio

• Commonly 0.85 – 1.15 equivalents depending on condensation efficiency and target β-lactam yield
• Process adjustment based on real-time monitoring of chiral purity and yield after side-chain construction

Downstream process integration

• Initial coupling or acylation step for β-lactam side chain elaboration
• Follows activation (e.g., by acid chloride formation) or ester hydrolysis as part of the synthetic sequence
• Downstream purification via preparative HPLC or crystallization

Final product types

• Non-natural side chain intermediates for β-lactam antibiotics (oral and parenteral forms)
• 7-ACA and 6-APA derivatives used in cephalosporin and penicillin API synthesis
• Finished antibiotic API for formulation

4. Intermediate for Custom Fine Chemicals and Specialty Analytical Standards

Custom synthesis and reference standard manufacturers incorporate this compound into the targeted functionalization processes leading to fine chemicals and analytical calibrators, especially where precise stereochemistry is required. Its application focuses on tightly-controlled, batch-tracked projects for industrial or research clients requiring assayable purity and certificate-backed traceability. The amount added is calculated based on the output requirement for analytical method development, standardization batches, or high-purity custom molecules.

Industry compliance standards

• ISO 17034 certification for reference material producers
• ISO/IEC 17025 for analytical laboratory quality assurance
• REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) compliance in the EU
• Custom order contracts adhering to specification sheets validated by QA

Typical usage ratio

• Varies from 50 mg to 5 g per batch for calibrator preparation – scaled to standard solution or test protocol needs
• In multi-step syntheses, passes through one or two intermediate functionalizations (0.9 – 1.2 equivalence)

Downstream process integration

• Solution-phase functionalization followed by crystallization or preparative isolation
• Monitored under validated method protocols for purity and isomeric content
• Certificate of Analysis and stability data generated at each critical stage

Final product types

• Stereochemically-defined fine chemicals for industrial R&D
• Reference analytical standards for chromatographic calibration
• Control samples for pharmaceutical quality laboratories